Is ERAS or EVGN more undervalued in 2026?

CirclFi compares Erasca, Inc. (ERAS) and Evogene Ltd. (EVGN) using 13 institutional-grade valuation models. ERAS has a Quality of Company score of 4.2/10 while EVGN scores 1.9/10.

Which is a better buy — ERAS or EVGN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ERAS and EVGN valuations compare?

ERAS at $12.20 and EVGN at $0.72 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ERAS vs EVGN Valuation Comparison 2026 — Intrinsic Value Analysis

ERAS

Biotechnology

Erasca, Inc.

Quality

4.2

out of 10

Value Trap

SAFE

Price

$12.20

Last close

Models

10/13

Active

EVGN

Biotechnology

Evogene Ltd.

Quality

1.9

out of 10

Value Trap

SAFE

Price

$0.72

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ERAS Fair Value	ERAS Upside	EVGN Fair Value	EVGN Upside
Bayesian DCF	Intrinsic	$3.70	-69.7%	$0.19	-73.5%
Earnings Power Value	Intrinsic	$9.40	-56.3%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	—	—	$4.11	+475.3%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ERAS vs EVGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ERAS vs EVGN — Which Stock Is More Undervalued?

ERAS scores higher with a 4.2/10 quality rating vs EVGN's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Erasca, Inc. (ERAS) and Evogene Ltd. (EVGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ERAS currently trades at $12.20 with a QOC of 4.2/10, while EVGN trades at $0.72 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).